Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy.
Jose C PastorSalvador Pastor-IdoateMarina López-PaniaguaMarta ParaFrancisco BlazquezEsther MurguiVerónica GarcíaRosa M Coco-MartínPublished in: Stem cell research & therapy (2023)
Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NEUROSTEM). NCT03173638. Registered June 02, 2017 https://clinicaltrials.gov/ct2/show/NCT03173638 .
Keyphrases
- phase ii
- clinical trial
- mesenchymal stem cells
- open label
- liver failure
- double blind
- phase iii
- bone marrow
- placebo controlled
- umbilical cord
- vascular endothelial growth factor
- respiratory failure
- diabetic retinopathy
- aortic dissection
- drug induced
- age related macular degeneration
- computed tomography
- cell therapy
- randomized controlled trial
- study protocol
- contrast enhanced
- magnetic resonance
- dual energy
- hematopoietic stem cell
- hepatitis b virus
- ischemia reperfusion injury
- magnetic resonance imaging
- low dose
- image quality
- positron emission tomography
- intensive care unit
- optical coherence tomography
- endothelial cells
- pet ct